Expression and Influence of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 and Vascular Endothelial Growth Factor in Diabetic Foot Ulcers

被引:25
|
作者
Li, Gongchi [1 ]
Zou, Xinhua [2 ]
Zhu, Youpeng [2 ]
Jing, Zhang [2 ]
Zhou, Lijun [2 ]
Wang, Dan [2 ]
Li, Binghui [2 ]
Chen, Zhenbing [1 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Liyuan Hosp Tongji Med Coll, Wuhan, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Wuhan Union Hosp, No 1277 Jlefang Ave, Wuhan, Hubei, Peoples R China
来源
关键词
diabetic foot ulcers (DFUs); wound infection; matrix metalloproteinase-9 (MMP9); tissue inhibitor of metalloproteinases-1 (TIMP1); vascular endothelial growth factor (VEGF); TISSUE INHIBITORS; MATRIX-METALLOPROTEINASE-9; ANGIOGENESIS; INFECTION; INFLAMMATION; DIAGNOSIS; MMPS; SKIN;
D O I
10.1177/1534734617696728
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 (MMP9/TIMP1) ratio is associated with poor ulcer healing, yet how the ratio of MMP9/TIMP1 changes in diabetic foot ulcers (DFUs) with infection and how these changes may affect wound healing remain unclear. Therefore, the objective of this investigation was to explore relationships among the MMP9/TIMP1 ratio, infection, and DFUs. After being informed of the details of this study, 32 patients signed consent forms. Skin biopsies were performed for all patients. Wound tissues were obtained from all patients with wounds, and healthy skin samples were collected from patients without wounds during orthopedic surgery. Microbial cultures were obtained using the samples from diabetic patients with wounds. All patients were divided into 4 groups according to colony-forming units (CFUs) per gram of tissue (> 1 x 10(6) or < 1 x 10(6)): group A (diabetic wounds with high quantities of bacteria), group B (diabetic wounds with low quantities of bacteria), group C (diabetic patients without wounds), and group D (nondiabetic patients with wounds). In addition, the biopsies were evaluated by both reverse transcription-quantitative polymerase chain reaction and Western blotting to assess the levels of MMP9, TIMP1, and vascular endothelial growth factor (VEGF). The results show that for both mRNA and protein, expression of MMP9 (fold change 1.14 +/- 0.12 vs 0.60 +/- 0.08 vs 0.39 +/- 0.09 vs 0.13 +/- 0.06, P <.01) decreased, whereas that of TIMP1 (1.01 +/- 0.09 vs 2.86 +/- 0.85 vs 4.88 +/- 0.83 vs 7.29 +/- 1.55, P <.01) and VEGF (1.01 +/- 0.22 vs 3.55 +/- 0.97 vs 5.72 +/- 0.55 vs 6.92 +/- 1.55, P <.01) increased from group A to group D. These results suggest that an increase in the MMP9/TIMP1 ratio in infected DFUs may induce a decrease in VEGF expression.
引用
收藏
页码:6 / 13
页数:8
相关论文
共 50 条
  • [1] Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 after Administration of Endotoxin in Diabetic Rats
    Seo, Ki Hyun
    Choi, Jae Sung
    Na, Joo Ok
    Uh, Soo Taek
    Kim, Yong Hoon
    Park, Choon Sik
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2006, 61 (03) : 256 - 264
  • [2] Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Endometriosis Menstrual Blood
    Madjid, Tita Husnitawati
    Ardiansyah, Dennis Fachmi
    Permadi, Wiryawan
    Hernowo, Bethy
    DIAGNOSTICS, 2020, 10 (06)
  • [3] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in perinatal asphyxia
    Sunagawa, Shinpei
    Ichiyama, Takashi
    Honda, Rie
    Fukunaga, Shinnosuke
    Maeba, Shinji
    Furukawa, Susumu
    BRAIN & DEVELOPMENT, 2009, 31 (08): : 588 - 593
  • [4] Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis
    Maitra, Subir R.
    Jacob, Asha
    Zhou, Mian
    Wang, Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2010, 3 (03): : 180 - 185
  • [5] Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in multiple sclerosis
    Boz, Cavit
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2006, 108 (06) : 618 - 618
  • [6] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in multiple sclerosis
    Gerlach, Raquel F.
    Tanus-Santos, Jose E.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2006, 108 (06) : 617 - 618
  • [7] Haemoxygenase-1 in coronary artery disease: a comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor
    Balakrishnan, B.
    Idriss, N.
    Lip, G. Y. H.
    Blann, A. D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 72 - 72
  • [8] Plasma haemoxygenase-1 in coronary artery disease A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor
    Idriss, Naglaa K.
    Lip, Gregory Y. H.
    Balakrishnan, Balu
    Jaumdally, Rumi
    Boos, Christopher J.
    Blann, Andrew D.
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (05) : 1029 - 1037
  • [9] EXPRESSION AND INFLUENCE OF MARTRIX METALLOPROTEINASE-9 (MMP-9)/TISSUE INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN DIABETIC FOOT ULCERS (DFUS)
    Li, G.
    Zou, X.
    Zhang, J.
    Zhu, Y.
    Jin, S.
    Li, B.
    WOUND REPAIR AND REGENERATION, 2016, 24 (02) : A16 - A16
  • [10] Expression of matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 in childhood acute lymphoblastic leukemia
    Mekawy, Mohamed A.
    Maksoud, Sahar S. Abdel
    Eissa, Doaa G.
    Abdelmaksoud, Abeer A.
    Ragab, Iman A.
    Sallam, Mahmoud T.
    Yousef, Adam A.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2012, 37 (04): : 274 - 280